Friday September 15, 10:04 am Eastern Time
Press Release
SOURCE: Biosonix Ltd.
Non-Invasive and Real-Time Blood Flow Systems Developed by Biosonix Ltd.
HOD HASHARON, Israel, Sept. 15 /PRNewswire/ -- Blood flow, the volume of blood flowing in a blood vessel per unit of time, is the basic determinant of organ perfusion. As a fundamental parameter in the viability of organs, blood flow is essential to practically all medical disciplines. Blood flow must be taken into account by the neurosurgeon who treats head trauma patients; by the vascular surgeon who performs stenting and other vascular procedures; by the cardiac surgeon during coronary artery bypass operations. To date, however, only indirect, invasive or non-immediate means have been available to ascertain adequate blood flow. Moreover, to date, no single technology has addressed all market needs pertaining to blood flow measurement.
Biosonix provides a medical and commercial first -- a new gold standard: an absolute value of blood flow, measured in real-time, directly and non-invasively, upon which quantitative, evidence-based medicine can be practiced. Biosonix breakthrough technology, utilizing angle-independent digital Doppler technology, is the basis for products that provide targeted solutions to cover a spectrum of needs: continuous hemodynamic monitoring with the FlowGuard(TM) system for neurosurgical and OR settings, intraoperative assessment with the InFlow(TM) system to replace the surgeons' qualitative manual pulsation, and fast diagnostics with the TotalFlow(TM) system for quantitative assessments in vascular surgery and dialysis units.
The Biosonix technology, though focused on real-time quantitative blood flow measurements, provides also a complete range of additional vascular parameters, including shear rate, accurate velocity, velocity profile, heart rate, pulsatility and resistive indices, vascular diameter, and much more.
The company's first products, the FlowGuard(TM) and the InFlow(TM), are presently in the process of being commercialized. Initial in-vitro experiments have been carried out successfully, and clinical trials are under preparation in various medical settings. The Biosonix concept has been enthusiastically received by leading physicians worldwide who eagerly expressed their desire and willingness to collaborate with the company.
Biosonix Ltd. is a privately held company, co-founded in 1998 by Dr. Dan Manor, Mr. Eli Levy and Mr. Roni Bibi. The three partners have extensive experience with ultrasound devices, and have led their previous venture, Medical Dynamics Ltd., into the world marketplace.
Biosonix is presently looking to utilize its' technological and clinical strengths in order to establish a successful strategic partnership with a company with strong market presence and sales capabilities. |
